Status:
COMPLETED
Study To Compare Single Dose Of Three Modified Release Formulations Of PF-04937319 With Immediate Release Material-Sparing-Tablet (IR MST) Formulation Previously Studied In Adults With Type 2 Diabetes Mellitus.
Lead Sponsor:
Pfizer
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
Study B1621015 will characterize bioavailability, tolerability and pharmacodynamics of three modified release formulations of PF-04937319 compared with the immediate release material-sparing-tablet (I...
Eligibility Criteria
Inclusion
- Adults with type 2 diabetes, on stable background metformin therapy either alone or in combination with another oral anti-diabetic agent (OAD) excluding thiazolidinediones (TZDs)
Exclusion
- Patients with cardiovascular event within 6 months of screening
- Patients with diabetic complications
- Female subjects who are pregnant or planning to become pregnant
- Subjects with unstable medical conditions (eg, hypertension)
Key Trial Info
Start Date :
September 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2015
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT02206607
Start Date
September 1 2014
End Date
January 1 2015
Last Update
March 4 2016
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
High Point Clinical Trials Center
High Point, North Carolina, United States, 27265
2
Clinical Trials of Texas, Inc.
San Antonio, Texas, United States, 78229